Skip to Main Content

Saral Mehra

MD, MBA, FACS
Associate Professor of Surgery (Otolaryngology); Section Chief, Head and Neck Surgery, Otolaryngology Surgery; Director, Head and Neck Oncologic and Reconstructive Surgery Fellowship, Surgery

Coauthors

Research Interests

Head and Neck Neoplasms; Health Services Research; Microsurgery; Minimally Invasive Surgical Procedures; Reconstructive Surgical Procedures

Public Health Interests

Cancer; Clinical Guidelines; Clinical Trials; Health Care Quality, Efficiency; Health Care Management; Health Economics; Vaccines; Health Systems Reform

Selected Publications

Clinical Trials

ConditionsStudy Title
Lip, Oral Cavity and Pharynx; Other Skin; Soft TissueA Randomized, Controlled, Open-Label, Phase 2 Study of Cemiplimab as a Single Agent and in Combination With RP1 in Patients With Advanced Cutaneous Squamous Cell Carcinoma
Esophagus; Larynx; Lip, Oral Cavity and Pharynx; Thyroid; Phase IA Phase 1, First-in-Human, Open-Label, Dose Escalation and Expansion Study of CUE-101 Monotherapy in Patients With HPV+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
Other SkinA Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Pembrolizumab Versus Placebo as Adjuvant Therapy Following Surgery and Radiation in Participants With High-risk Locally Advanced Cutaneous Squamous Cell Carcinoma (LA cSCC) (KEYNOTE-630)
Esophagus; Larynx; Lip, Oral Cavity and PharynxRandomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Lip, Oral Cavity and PharynxPhase II Randomized Trial of Neo-Adjuvant Chemotherapy Followed by Surgery and Post-Operative Radiation Versus Surgery and Post-Operative Radiation for Organ Preservation of T3 and T4a Nasal and Paranasal Sinus Squamous Cell Carcinoma (NPNSCC)
Larynx; Lip, Oral Cavity and PharynxSingle-Arm Phase II Trial of Dual Inhibition of EGFR With Afatinib and Cetuximab With Correlative Studies in the Second-Line Treatment of Recurrent or Metastatic Squamous Cell Cancers of the Head and Neck